/ /

  • linkedin
  • Increase Font
  • Sharebar

    Allergan acknowledges revised, unsolicited Valeant proposal


    Irvine, CA—Allergan has publicly acknowledged that Valeant Pharmaceuticals International, along with Pershing Square Capital Management, have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the company.

    The revised proposal includes a total of 0.83 of Valeant common shares, $72 in cash per share of common stock of Allergan, and a contingent value right related to DARPin sales.

    The original proposal, which came in April, consisted of 0.83 shares of Valeant stock and $48.30 in cash. However, Allergan’s board swiftly rejected the offer.

    Further distancing itself from Valeant’s proposal, last week Allergan filed an investor presentation with the Securities and Exchange Commission and posted the presentation to its website detailing its initial concerns about the sustainability of Valeant’s business model.


    Continue to page 2

    Rose Schneider Krivich
    Rose is the content specialist for Medical Economics.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results